ExpreS2ion announces initiation of a Wuhan Coronavirus vaccine program
Hørsholm, Denmark, February 6, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the initiation of a Wuhan Coronavirus (2019-nCoV) vaccine program. ExpreS2ion will produce viral antigens needed for diagnostics and vaccine research, focused on internal vaccine development efforts. The program’s first stage has a timeline of two-three months and is contained within ExpreS2ion’s existing budget.ExpreS[2]ion will apply its clinically validated Drosophila S2 insect cell expression system, ExpreS[2], to produce 2019-